AlzeCure Pharma AB AI Stock Analysis
Want to see SE:ALZCUR full AI Analyst Report?
AlzeCure Pharma AB (ALZCUR) AI Stock Analysis
AlzeCure Pharma AB
(Nasdaq OMX AB:ALZCUR)
The score is held down primarily by weak financial performance (no revenue, large losses, and substantial ongoing cash burn with declining equity), implying continued funding dependence. Technicals are a supportive offset with the stock above major moving averages and non-overbought momentum, while valuation is less supportive due to a high P/E and no dividend yield data.
AlzeCure Pharma AB (ALZCUR) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 882.54M
- Dividend Yield
- ―
- Average Volume (3M)
- 310.93K
- Price to Earnings (P/E)
- 10.7
- Beta (1Y)
- 0.33
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Sweden
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
AlzeCure Pharma AB Business Overview & Revenue Model
Company Description
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates base...
How the Company Makes Money
AlzeCure Pharma AB’s business model is typical of an early-stage biotech/pharma R&D company: it primarily creates value by discovering and developing drug candidates and then seeking to monetize them through partnering transactions and, potentially,...
AlzeCure Pharma AB Financial Statement Overview
Summary
Weak financial profile typical of a development-stage biotech: zero revenue, persistent and sizable losses (TTM net loss ~59.2M; EBIT ~-62.9M) and heavy cash burn (TTM operating cash flow/free cash flow ~-41.0M). Balance sheet leverage is low (TTM debt ~2.29M vs equity ~11.23M), but equity has fallen sharply over time, increasing financing risk.
Income Statement
12Very NegativeBalance Sheet
55NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.19M | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -602.00K | -1.27M | -293.00K | -476.00K | -570.00K | -576.00K |
| EBITDA | 11.88M | -48.10M | -35.70M | -37.87M | -55.67M | -77.20M |
| Net Income | 12.84M | -47.65M | -35.23M | -37.17M | -56.04M | -77.78M |
Balance Sheet | ||||||
| Total Assets | 238.60M | 59.04M | 34.44M | 32.00M | 70.84M | 45.65M |
| Cash, Cash Equivalents and Short-Term Investments | 231.93M | 50.34M | 31.50M | 29.10M | 25.58M | 41.74M |
| Total Debt | 1.72M | 5.12M | 0 | 0 | 0 | 0 |
| Total Liabilities | 20.12M | 26.12M | 8.25M | 8.23M | 10.35M | 12.67M |
| Stockholders Equity | 218.48M | 32.92M | 26.18M | 23.77M | 60.48M | 32.97M |
Cash Flow | ||||||
| Free Cash Flow | 110.55M | -34.59M | -35.25M | 3.06M | -99.91M | -70.69M |
| Operating Cash Flow | 110.55M | -34.59M | -35.12M | 3.06M | -99.91M | -70.64M |
| Investing Cash Flow | 0 | 0 | -124.00K | 7,000 | 0 | -54.00K |
| Financing Cash Flow | 73.43M | 53.43M | 37.65M | 459.00K | 83.75M | 0 |
AlzeCure Pharma AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZCUR, the sentiment is Negative. The current price of 6.40 is below the 20-day moving average (MA) of 6.47, below the 50-day MA of 7.08, and above the 200-day MA of 4.30, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 44.17 is Neutral, neither overbought nor oversold. The STOCH value of 79.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ALZCUR.
AlzeCure Pharma AB Peers Comparison
Overall Rating
SE:CAMX78Outperform
SE:SANION77Outperform
SE:BIOA.B65Neutral
SE:ALZCUR50Neutral
SE:ALZ44Neutral
SE:IRLAB.A38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | SEK 45.12B | 58.66 | 16.50% | ― | 2.96% | -4.07% | |
| 77Outperform | SEK 1.64B | 8.89 | 29.71% | ― | 24.98% | -31.44% | |
| 65Neutral | SEK 27.51B | 260.50 | 5.18% | 0.69% | -46.09% | -90.13% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | SEK 882.54M | 10.67 | 105.09% | ― | ― | ― | |
| 44Neutral | SEK 100.82M | -1.88 | -15.44% | ― | -100.00% | 40.79% | |
| 38Underperform | SEK 126.11M | -1.30 | -97.06% | ― | -21.20% | 68.24% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ALZCUR | AlzeCure Pharma AB | 6.40 | 4.54 | 243.16% | |
| SE:CAMX | Camurus AB | 745.00 | 123.00 | 19.77% | |
| SE:ALZ | Alzinova AB | 0.32 | -1.23 | -79.42% | |
| SE:BIOA.B | BioArctic AB Class B | 310.00 | 25.49 | 8.96% | |
| SE:SANION | Saniona AB | 11.91 | -4.31 | -26.57% | |
| SE:IRLAB.A | IRLAB Therapeutics AB Class A | 0.85 | -1.37 | -61.82% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026
